MULTIPHARMA GROUP
ActiveSummary
MULTIPHARMA GROUP has been active since 1912 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €131.2m and a net result of -€60,057. Equity is growing by ~13.8% per year across the filed fiscal years. The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Score 2024
Axes · tick = 2023
Profitability37▼-63
Solvency100=
Growth52▼-26
Track record100
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000,000 at 30 days acceptable
Liquidity tight (current ratio 1.06 against 1.1 in 2023; short-term debt: 0.4% and cash: 0.1% of total assets), and 0.4% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
99.6%
Return on assets
0%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
not confirmed
2024
38 d early
2023
14 d early
2022
2 d late
2021
6 d early
2020
40 d early
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 5 accounts on average 19 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check Which other companies belong to the same group?MULTIPHARMA GROUP · 10 companies How does this company compare with its sector?Sector benchmark
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, unclassified schema, statutory accounts
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€60,057
2023 · €43.8m
Working capital
€33,015▼ 39.5%
2023 · €54,602
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Operating result-€139,689▲ 14.7%-€127,992▲ 8.4%-€224,454▼ 75.4%-€213,737▲ 4.8%-€171,565▲ 19.7%
Net result-€98,981€6.0m-€115,388€43.8m-€60,057
Equity€83.5m▼ 0.1%€89.1m▲ 6.7%€88.5m▼ 0.7%€131.8m▲ 48.9%€131.2m▼ 0.4%
Total assets€85.3m▲ 2.0%€89.6m▲ 5.1%€89.0m▼ 0.7%€132.3m▲ 48.7%€131.8m▼ 0.4%
Debt€1.8m▲ 9,679%€524,790▼ 70.2%€527,352▲ 0.5%€527,033▼ 0.1%€522,997▼ 0.8%
Working capital€1.0m▼ 81.1%€787,045▼ 23.3%€664,957▼ 15.5%€54,602▼ 91.8%€33,015▼ 39.5%
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €171,565 in 2024 against €213,737 in 2023; the loss shrinks.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €131.8m
Fixed assets
€131.2m ▼ 0.4%
Current assets
€556,012 ▼ 4.4%
Equity and liabilities €131.8m
Equity
€131.2m ▼ 0.4%
Debt
€522,997 ▼ 0.8%
Debt's share of the balance-sheet total stays at 0.4%.
Key figures and ratios
Current ratio
1.06▼
2023 · 1.10
Debt to equity
0.00▼
2023 · 0.00
ROE
0.0%▼
2023 · 33.2%
ROA
0.0%▼
2023 · 33.1%
Debt ≤ 1 year
€522,997▼
2023 · €527,033
Income taxes
-€2,153
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Operating income70/76A | - | €634 | - | €1,016 | €239,174 | ▲ 23,441% |
| Other operating income74 | - | €634 | - | €1,016 | €602 | ▼ 40.7% |
| Non-recurring operating income76A | - | - | - | - | €238,572 | - |
| Operating charges60/66A | - | €128,626 | €224,454 | €214,753 | €410,739 | ▲ 91.3% |
| Services and other goods61 | - | €119,930 | €220,098 | €209,612 | €201,768 | ▼ 3.7% |
| Other operating charges640/8 | - | €8,696 | €4,356 | €5,141 | €19,030 | ▲ 270% |
| Non-recurring operating charges66A | - | - | - | - | €189,941 | - |
| Operating profit (loss)9901 | -€139,689 | -€127,992 | -€224,454 | -€213,737 | -€171,565 | ▲ 19.7% |
| Financial income75/76B | - | €6.1m | €115,573 | €44.0m | €111,785 | ▼ 99.7% |
| Recurring financial income75 | €58,820 | €118,368 | €115,573 | €112,407 | €105,175 | ▼ 6.4% |
| Income from financial fixed assets750 | - | €118,368 | €115,573 | €112,407 | €105,175 | ▼ 6.4% |
| Non-recurring financial income76B | - | €6.0m | - | €43.9m | €6,610 | ▼ 100.0% |
| Financial charges65/66B | - | €15,229 | €4,354 | €2,325 | €2,430 | ▲ 4.5% |
| Recurring financial charges65 | €18,112 | €10,100 | €4,354 | €2,325 | €2,430 | ▲ 4.5% |
| Debt charges650 | €16,666 | - | - | - | - | - |
| Other financial charges652/9 | - | €10,100 | €4,354 | €2,325 | €2,430 | ▲ 4.5% |
| Non-recurring financial charges66B | - | €5,129 | - | - | - | - |
| Profit (loss) for the period before taxes9903 | -€98,981 | €6.0m | -€113,235 | €43.8m | -€62,210 | ▼ 100% |
| Income taxes67/77 | - | -€836 | €2,153 | - | -€2,153 | - |
| Taxes670/3 | - | - | €2,153 | - | - | - |
| Tax adjustments and reversals of tax provisions77 | - | €836 | - | - | €2,153 | - |
| Profit (loss) for the period9904 | -€98,981 | €6.0m | -€115,388 | €43.8m | -€60,057 | ▼ 100% |
| Profit (loss) for the period to be appropriated9905 | -€98,981 | €6.0m | -€115,388 | €43.8m | -€60,057 | ▼ 100% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €85.3m | €89.6m | €89.0m | €132.3m | €131.8m | ▼ 0.4% |
| Fixed assets21/28 | €84.2m | €88.3m | €87.8m | €131.8m | €131.2m | ▼ 0.4% |
| Financial fixed assets28 | €84.2m | €88.3m | €87.8m | €131.8m | €131.2m | ▼ 0.4% |
| Affiliated companies280/1 | - | €88.3m | €87.8m | €131.7m | €131.2m | ▼ 0.4% |
| Participating interests280 | - | €82.3m | €82.3m | €126.2m | €126.2m | = |
| Amounts receivable281 | - | €6.0m | €5.5m | €5.5m | €5.0m | ▼ 9.1% |
| Other financial fixed assets284/8 | - | €46,650 | €46,650 | €46,650 | €2,479 | ▼ 94.7% |
| Shares284 | - | €46,650 | €46,650 | €46,650 | €2,479 | ▼ 94.7% |
| Current assets29/58 | €1.1m | €1.3m | €1.2m | €581,635 | €556,012 | ▼ 4.4% |
| Amounts receivable within one year40/41 | €300,446 | €44,047 | €126,076 | €250,383 | €360,896 | ▲ 44.1% |
| Other amounts receivable41 | - | €44,047 | €126,076 | €250,383 | €360,896 | ▲ 44.1% |
| Current investments50/53 | €5,718 | €5,718 | €5,718 | €5,718 | €5,718 | = |
| Other investments51/53 | - | €5,718 | €5,718 | €5,718 | €5,718 | = |
| Cash at bank and in hand54/58 | €782,913 | €1.2m | €967,389 | €229,037 | €87,566 | ▼ 61.8% |
| Deferred charges and accrued income490/1 | - | €99,742 | €93,126 | €96,497 | €101,832 | ▲ 5.5% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €85.3m | €89.6m | €89.0m | €132.3m | €131.8m | ▼ 0.4% |
| Equity10/15 | €83.5m | €89.1m | €88.5m | €131.8m | €131.2m | ▼ 0.4% |
| Contributions10/11 | - | €8.4m | €8.4m | €8.4m | €8.4m | = |
| Revaluation surpluses12 | - | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Reserves13 | €74.1m | €74.1m | €74.1m | €74.1m | €74.1m | = |
| Non-distributable reserves130/1 | - | €1.2m | €1.2m | €1.2m | €1.1m | ▼ 1.6% |
| Reserves not available under the articles1311 | - | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Other1319 | - | €74,596 | €74,596 | €74,596 | €55,846 | ▼ 25.1% |
| Tax-exempt reserves132 | - | €31.8m | €31.8m | €31.8m | €13.2m | ▼ 58.6% |
| Distributable reserves133 | - | €41.1m | €41.1m | €41.1m | €59.8m | ▲ 45.4% |
| Profit (loss) carried forward14 | €74,135 | €5.6m | €4.9m | €48.3m | €47.7m | ▼ 1.2% |
| Amounts payable17/49 | €1.8m | €524,790 | €527,352 | €527,033 | €522,997 | ▼ 0.8% |
| Amounts payable after more than one year17 | €1.7m | - | - | - | - | - |
| Amounts payable within one year42/48 | €62,573 | €524,790 | €527,352 | €527,033 | €522,997 | ▼ 0.8% |
| Trade debts44 | €3,120 | €7,553 | €8,100 | €7,787 | €3,750 | ▼ 51.8% |
| Suppliers440/4 | - | €7,553 | €8,100 | €7,787 | €3,750 | ▼ 51.8% |
| Other amounts payable47/48 | - | €517,237 | €519,252 | €519,246 | €519,247 | = |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€98,981 | €6.0m | -€115,388 | €43.8m | -€60,057 | ▼ 100% |
| Operating cash flow (approximation) | -€98,981 | €6.0m | -€115,388 | €43.8m | -€60,057 | ▼ 100% |
| Investment in fixed assets (approximation) | - | -€4.1m | €500,000 | -€43.9m | €544,171 | ▲ 101% |
| Change in cash | - | €379,415 | -€194,939 | -€738,352 | -€141,471 | ▲ 80.8% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
30-06
NBB filing
Annual accounts filed
fiscal year 2024 · consolidated
23-06
NBB filing
Annual accounts filed
fiscal year 2024 · unclassified schema
2024
31-12
NBB filing
Annual accounts filed
fiscal year 2023 · consolidated
17-07
NBB filing
Annual accounts filed
fiscal year 2023 · unclassified schema
2023
31-12
Financial
Back to profitnet €43.8m
Net result €43.8m after one loss-making year.
31-12
Financial
Equity above €100mEq €131.8m ▲48.9%
Equity rises from €88.5m to €131.8m.
02-08
NBB filing
Annual accounts filed
fiscal year 2022 · consolidated · 2 days late
02-08
NBB filing
Annual accounts filed
fiscal year 2022 · unclassified schema · 2 days late
2022
31-12
Financial
Weakest financial yearnet -€115,388
Net result drops to -€115,388, the lowest in the series; recovery starts the following year.
27-07
NBB filing
Annual accounts filed
fiscal year 2021 · consolidated
25-07
NBB filing
Annual accounts filed
fiscal year 2021 · unclassified schema
2021
31-12
Financial
Back to profitnet €6.0m
Net result €6.0m after one loss-making year.
Show earlier events
05-07
NBB filing
Annual accounts filed
fiscal year 2020 · consolidated
21-06
NBB filing
Annual accounts filed
fiscal year 2020 · unclassified schema
2019
31-12
Financial
Liquidity times 9current ratio 302.01
Current ratio from 34.19 to 302.01; short-term debt falls from €19,544 to €18,024.
31-12
Financial
Equity above €50mEq €83.6m ▲1,873%
2 profitable years in a row build equity to €83.6m.
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 106 acts read
About the unread acts
We know of 106 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
106 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Anderlecht · 1 establishment unit since 1901
Ground area
4.3 ha
Building footprint
9,613 m²
Volume, LiDAR
98,971 m³
2 parcels, Brussels · tallest building 19.0 m, ±5 floors. Linked by address, not a title deed.
12
companies at this address
See who is registered here
1 establishment unit
Lennikse Baan 900, 1070 Anderlecht
since 19012.012.902.626
2 parcels
Brussels
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21307F0194/00D000 | Brussels | 3.7 ha | 1 · 8,156 m² | 19.0 m · 3 fl. |
| 21307F0088/00D000 | Brussels | 6,616 m² | 1 · 1,456 m² | 18.4 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Heads the group
MULTIPHARMA GROUP
10 companies
Group, risk and exposure
Owners and holdings
17 owners · 1 holding · 9 subsidiaries in the treeOwners 17
-
25.16%
-
16.79%
-
10.47%
-
9.9%
- 9.9%
-
9.3%
- Sourceown accounts 20245.38%
- Sourceown accounts 20241.94%
-
1.91%
-
1.47%
Show 7 more owners
-
1.4%
-
1.22%
-
0.41%
-
0.31%
-
0.28%
-
0.28%
-
0.02%
Holdings 1
-
100%
All subsidiaries, including indirect ones 9
Companies in which this company or one of its subsidiaries holds more than half, or which it consolidates according to the LEI register.
Multipharma 100%8 subsidiaries
- APOLIERCONSULT 100%
- APOPLUS 100%
- APOTHEEK SMISHOEK 100%
- APOTHEEK WILLEBROEK 100%
- FARMANNSO 100%
- IMMOBOX 100%
- PHARMACIE DEBELLE 100%
- STENAPHAR 100%
According to the 2024 annual accounts of MULTIPHARMA GROUP and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Identification & contact
Identification
Legal formCooperative company
Founded17-07-1912
Fiscal year end31-12
E-invoicing
Not found in the Peppol register
No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.
What can you do?
Try sending from your invoicing software; if that fails, ask the customer whether they already receive via Peppol.
If the customer is not ready yet, you may send the invoice another way, for example as a PDF; if electronically, with their agreement on a secure alternative. That invoice is valid; the customer risks a penalty. FPS Finance
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
General meetings
2 convocationsExtraordinary general meeting
Agenda
DE L’ASSEMBLEE GENERALE ORDINAIRE DU 10 JUIN 2021 À 10H 1. Rapport de gestion du Conseil d’administration et rapport du commissaire sur l’exercice social clôturé au 31 décembre 2020; 2. Approbation des comptes annuels arrêtés au 31 décembre 2020; 3. Affectation du résultat; 4. Décharge aux administrateurs et au commissaire; 5. Démissions et nominations statutaires; 6. Communication des comptes consolidés au 31 décembre 2020; 7. Divers; 8. Lecture et approbation du procès-verbal de l’AGO de ce 10 juin 2021. ORDRE DU JOUR DE L’ASSEMBLEE GENERALE EXTRAORDINAIRE DU 10 JUIN 2021 À 11h 1. - Approbation du projet de fusion établi le 18 mars 2021 par les organes de gestion de la société coopérative ...
Extraordinary general meeting
Agenda
1. Goedkeuring van het fusievoorstel opgesteld op 19 september 2019 door de bestuursorganen van de coöperatieve vennootschap met beperkte aansprakelijkheid « MULTIPAR », over te nemen vennoot- schap, en van de coöperatieve vennootschap met beperkte aansprake- lijkheid « MULTIPHARMA GROUP », overnemende vennootschap opgesteld overeenkomstig artikel 693 van het Wetboek van Vennoot- schappen en neergelegd ter griffie van de Franstalige ondernemings- rechtbank te Brussel. voorstel om het schriftelijk en gedetailleerd verslag van het bestuurs- orgaan over de fusie overeenkomstig artikel 694 van het Wetboek van vennootschappen af te zien en om het verslag van de commissaris over het fusievoorstel ...